

Manufacturer & Exporter of Male Condoms, Female Condoms, Water based Lubricants & In Vitro Diagnostics (IVD) Kits

Date: - 31/07/2023

To.

Department of Corporate Services,

BSE LIMITED,

Phiroze Jeejeebhoy Towers,

Dalal Street.

Mumbai - 400 001

SCRIP CODE: 530843

The National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor, Bandra-Kurla

Complex, Bandra (East),

Mumbai - 400051

Fax No. - 6641 8125 / 26

SCRIP CODE: CUPID

Subject: - Outcome of Board Meeting and Financial Results for Quarter ended 30th June, 2023

Dear Sir / Madam,

With reference to captioned subject, we attached herewith the detail statement of outcome of Board Meeting and Financial Results for quarter ended 30th June, 2023 pursuant to regulation 30 and regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 respectively.

Kindly take the same on your records and acknowledge the receipt.

By the order of the Board of Directors

For Cupid Limited

Saurabh V. Karmase

Company Secretary and Compliance Officer

Factory & Registered Office:

+91 2551 230280 / 230772

www.cupidlimited.com info@cupidlimited.com

CIN No.: L25193MH1993PLC070846





# CUPID LIMITED

Manufacturer & Exporter of Male Condoms, Female Condoms, Water based Lubricants & In Vitro Diagnostics (IVD) Kits

## **OUTCOME OF BOARD MEETING**

July 31st, 2023:

The Board of Directors of the Cupid Limited at its meeting held on July 31st, 2023, inter alia, had considered and approved the following matters:-

Commencement time of Board Meeting: - 4.23 P.M.

Conclusion time of Board Meeting: - 4.55 P.M.

- Quarterly reports submitted to BSE Limited and National Stock Exchange of India Limited for quarter ended 30<sup>th</sup> June, 2023 were considered and reviewed by the Board.
- 2. Unaudited Financial Results for quarter ended 30<sup>th</sup> June, 2023 were considered and adopted by the Board. (Financial Results as attached)
- The Directors Report for year ended 31<sup>st</sup> March, 2023 was considered and approved by the Board.
- The Notice to Members / Shareholders for 30<sup>th</sup> Annual General Meeting of the company was considered and approved by the Board.
- Mr. Shailesh Kachalia, Practicing Company Secretary, appointed as Scrutiniser for 30<sup>th</sup> Annual General Meeting of the company. (Profile as attached)

Place: - Mumbai

Date: - 31/07/20233

By the order of the Board of Directors

For Cupid Limited

Saurabh V. Karmase


Company Secretary and Compliance Officer

Factory & Registered Office:

CIN No.: L25193MH1993PLC070846









Partners:
Sohan Chaturvedi FCA
Chaturvedi V N FCA
Noshir B Captain
Rajiv Chauhan ACA
Neha Chauhan ACA
Shristi Chaturvedi ACA



## Chaturvedi Sohan & Co.

## **Chartered Accountants**

FRN - 118424W

Independent Auditor's Review Report on the Quarterly and Year to date Unaudited Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Limited Review Report to The Board of Directors CUPID LIMIED

- 1. We have reviewed the accompanying statement of unaudited financial results of Cupid Ltd (the "Company") for the quarter ended June 30, 2023 and year to date from April 01, 2023 to June 30, 2023, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with standards on Auditing specifies under section 143(10) of the Act. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid' Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder

1

and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SRBI (Listing Obligation and Disclosure Requirement) Regulation 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi Sohan & co.

**Chartered Accountants** 

FRN: 118424W

Vivekanand Chaturvedi

Partner

Membership No. 106403

UDIN: 23106403BGPOSF6318

Place: Mumbai

Date :31st July,2023.

## Cupid Limited

CIN No: L25193MH1993PLC070846

Regd. Office :- A-68, M.I.D.C. (Malegaon), Sinnar, Nashik – 422113, Maharashtra, India. Ph:- 02551-230280, Fax:- 02551-230279, Website: www.cupidlimited.com, Email- info@cupidlimited.com

## Statement of Unaudited Financial Results for the Quarter Ended 30th June, 2023

(₹ in lacs except EPS, unless otherwise stated)

		(	Quarter Ended O	n	Year Ended on
S.No.	Particulars	30-Jun-2023	31-Mar-2023	30-Jun-2022	31-Mar-2023
		( Unaudited )	(Audited)	( Unaudited )	( Audited )
1	Revenue from operation	3,367.60	4,149.81	3,081.62	15,932.72
2	Other Non - operation Incomes	152.17	198.96	67.25	476.97
	Total Income	3,519.77	4,348.77	3,148.87	16,409.69
3	Expenses				
a)	Cost of Material Consumed	1.187.28	1,587.08	1,619.06	6,572.92
b)	Change in Inventories	(6.07)	239.49	(145.29)	(71.68
c)	Employee benefit expenses	487.57	488.84	285.68	1,376.68
d)	Finance costs	40.32	56.94	7.80	78.82
e)	Depreciation	71.40	82.94	65.21	296.93
f)	Other Expenses	1,516.70	774.48	743.67	3,924.13
	Total Expenses	3,297.20	3,229.76	2,576.13	12,177.79
4	Profit from Continuing Operation Before	222,57	1,119.01	572.74	4,231.90
	Exceptional items and Taxes				4,231.90
5	Profit From Ordinary Activities Before Tax	222.57	1,119.01	572.74	4,231.90
6 a)	Less : Tax Expenses	00.10	10101		I Wars and was
	Income tax for current quarter/ year	88.18	194.26	170.96	1,022.07
b)	Short / (Excess) provision of earlier years			-	3.5
c)	Deferred Tax Expenses / (Credit)	(81.40)	91.20	(61.66)	51.55
7	Net Profit / (Loss) From Ordinary Activities after tax for the period	215.79	833.55	463.44	3,158.28
8	Other Comprehensive Income / (Loss) (Net of Tax)				
a)	Item that will not be reclassified to profit and loss account				
(1)	Remeasurement of employee defined benefit obligation	-	(7.56)	(#)	(16.49
(ii)	Income Tax relating to items that will not be reclassified to profit or loss	-	1.90	-	4.15
9	Total Comprehensive Income (after tax) for the period	215.79	827.89	463.44	3,145.94
10	Paid up Equity Share Capital (Face value Rs.10/-)	1,333.80	1,333.80	1,333.80	1,333.80
11	Earning Per Share (EPS) ( * Not Annualised)				
(a)	Basic EPS (Amount is ₹)	1.62*	6.25*	3.47*	23.68
(b)	Diluted EPS ( Amount is ₹ )	1.61*	6.22*	3.47*	23.57



Notes to the Quarterly Result: -

1. The above financial results have been reviewed and recommended for approval by the Audit

Committee to the Board of Directors and have been approved by the Board of Director at its

meeting held on 31st July, 2023.

2. Financial results for all the periods presented have been prepared in accordance with the

recognition and measurement principle of Ind AS notified under the Companies (Indian

Accounting Standard) Rules, 2015 as amended from time to time.

3. The company's business operation comprises of operating segments viz., Male and Female

contraceptives, other relevant products and In Vitro Devices (IVD).

4. The Board of Directors authorised Mr. Sunil Sureka, Independent director to sign the

standalone financial results of the company for quarter ended 30th June, 2023.

5. The figures for quarter ended 31st March, 2023 are arrived at difference between audited

figures in respect of full financial year and published figure upto nine months of relevant

financial year.

6. During quarter ended 30th June, 2023, the Company has transferred unpaid and unclaimed

dividend of INR 10,07,588 and 960 unclaimed shares to IEPF.

7. During the quarter other expenses has increased due to the payment of ₹ 4.40 Cr as damages

to meet the contractual terms.

8. The previous period / year financial figures have been regrouped / rearranged wherever

necessary to make them comparable.

9. The results of the Company are available for investors at https://www.cupidlimited.com/,

https://www.nseindia.com/ and https://www.bseindia.com/

Place: Mumbai

For and on behalf of

Date: 31st July. 2023

200

Cupid Limited

(Independent Director)



Particular   Particular   Society	SEGMENT INFORM	Cupid Limited INFORMATION FOR THE QUARTER ENDED 30th June, 2923	TER ENDED 30th J	une, 2923	
30Jun-2023 31-Mar-2023 (Unaudited) (Audited)			Quarter Ended on		Year Ended on
3,352,62 4,120.19 14.98 29.61 152.17 198.97 3,519.77 4,348.77 3,519.77 4,348.77 152.17 198.97 152.17 198.97 152.17 198.97 152.17 1,119.01 222.57 1,119.01 1,774.24 10,613.68 11,774.24 10,613.68 18,725.67 1,459.33 1,616.16 22.08 58.99 189.47 338.28	Particular	30-Jun-2023	31-Mar-2023	30-Jun-2022	31-Mar-2023
3,352.62 4, 14.98 152.17 4, 3,519.77 4, 3,519.77 4, 1,52.17 1, 1,52.17 1, 1,429.33 1, 1,459.33 1, 1,459.33 1,		( Unaudited )	( Audited )	( Unaudited )	( Audited )
3,519.77 4,  3,519.77 4,  3,519.77 4,  103.92 (33.52) 152.17 152.17 222.57 1,  6,521.73 7,  822.31 11,774.24 10,  1,459.33 1, 22.08 189.47	1 Segment Revenue  a) Male and Female Contracentives & Jelly	0) 058 8	4 170 19	3 081 48	15 892 48
3,519.77 4,  3,519.77 4,  103.92 (33.52) 152.17 1,72.17 6,521.73 7, 822.31 11,774.24 10, 1459.33 1,459.33 1,459.33 1,459.47	b) In Vitro Devices (IVD)	14.98	29.61	0.14	40.23
3,519.77 4,  3,519.77 4,  103.92 (33.52) 152.17 1,72.17 6,521.73 7, 822.31 11,774.24 10, 11,459.33 1,459.33 1,459.33 1,459.47	c) Others / Unallocated	152.17	198.97	67.25	476.98
3,519.77 4,  103.92 (33.52) 152.17 1,72.17 6,521.73 7, 822.31 11,774.24 10, 11,459.33 1,459.33 1,459.33 1,459.47	Total	3,519.77	4,348.77	3,148.87	16,409.69
3,519,77 4,  103.92 (33.52) 152.17 5,521.73 7, 822.31 11,774.24 10, 19,118.28 1,459.33 1,459.33 1,459.33 1,459.47	Less: Inter Segment Revenue			,	
(33.52) (33.52) (52.17) (5.521.73) (6.521.73) (7.74.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.24) (10.774.	Gross Revenue from sale of product & Service	3,519.77	4,348.77	3,143.87	16,409.69
Contraceptives & Jelly (33.52)  1VD)  cd  Tax  Contraceptives & Jelly (5,521.73)  1VD)  Contraceptives & Jelly (6,521.73)  1VD)  11,774.24 10,  18,774.24 118,  IP,118.28 18,  Contraceptives & Jelly (1,459.33)	2 Segment Results Profit/(Loss) Before Tax				
(33.52)   (52.17)   (52.17)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)   (7.14)	a) Male and Female Contraceptives & Jelly	103.92	943.67	19.095	3,897.86
Tax  Tax  Contraceptives & Jelly  1,459.33  1,459.33  1,650  1,459.33  1,660  1,459.33  1,660  1,459.33  1,660  1,459.33  1,660  1,459.47	b) In Vitro Devices (IVD)	(33.52)	(23.63)	(55.12)	(142.94)
Tax       222.57       1,1         Contraceptives & Jelly       6,521.73       7,3         IVD)       11,774.24       10,6         Contraceptives & Jelly       19,118.28       18,7         Contraceptives & Jelly       1,459.33       1,6         Device (IVD)       22.08       1,6         33       1,89.47       33	c) Others / Unallocated	152.17	198.97	67.25	476.98
Contraceptives & Jelly 6,521.73 7,3 1VD) 11,774.24 10,6 11,774.24 10,6 11,774.24 10,6 11,774.24 10,6 18,7 11,774.24 11,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459	Total Profit Before Tax	222.57	1,119.01	572.74	4,231.90
Contraceptives & Jelly 6,521.73 7,3 1VD) 822.31 7,3 1VD) 11,774.24 10,6 10,6 11,774.24 10,6 18,7 10,6 11,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.33 1,6 1,459.	3 Segment Assets				
VD )   822.31   7.74.24   10,6   11,774.24   10,6   11,774.24   10,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,459.33   1,6   1,	a) Male and Female Contraceptives & Jelly	6,521.73	7,390.09	6,026.35	7,390.09
Contraceptives & Jelly 1,459.33 1,6 22.08 189.47 3	b) In Vitro Devices (IVD)	822.31	721.90	596.30	721.90
Contraceptives & Jelly 1,459.33 1,6 22.08 189.47 3	c) Unallocated	11,774.24	10,613.68	10,057.04	10,613.68
Contraceptives & Jelly 1,459.33 1,6 22.08 28.47	Total Assets	19,118.28	18,725.67	16,679.69	18,725.67
1,459.33 i.,6 22.08 189.47	4 Segment Liabilities				5
22.08	a) Male and Female Contraceptives & Jelly	1,459.33	1,616.16	1,487.04	1,616.16
189.47	b) Vitro Diagnostic Device (IVD)	22.08	58.99	84.83	58.99
	c) Unallocated	189.47	338.28	413.65	338.28
Total Liabilities 2,013.43	Total Liabilities	1,670.88	2,013,43	1,985.52	2,013.43

## CS SHAILESH KACHALIA

Contact No.: +91-9892534153 E-Mail: shaileshmay@gmail.com

#### QUALIFICATIONS. :

- 1. B.COM. (HONS) MUMBAI UNIVERSITY (1977)
- 2. LLB MUMBAI UNIVERSITY (1981)
- 3. FELLOW MEMBER OF THE INSTITUTE OF COMPANY SECRETARIES OF INDIA (1981)
- 4. SEVEN DAYS COURSE ORGANIZED BY INDIAN MERCHANT CHAMBERS MUMBAI IN ARBITRATION.

#### EXPERIENCE AS FULL TIME COMPANY SECRETARY:-

I WORKED AS FULL TIME COMPANY SECRETARY FROM NOVEMBER 1981 TO DECEMBER 1994 WITH FOLLOWING ORGANISATIONS: -

- 1. 12 MONTHS WITH M/s. WARIOR INVESTMENTS LIMITED (UNLISTED CO.)
- 2. 18 MONTHS WITH M/S. UNIVERSAL STARCH CHEM ALLIED INDUSTRIES LIMITED (LISTED CO.)
- 3. 66 MONTHS WITH M/s. MODERN MILLS LIMITED (LISTED CO.)
- 4. 6 MONTHS WITH BEE ELETRONICS LIMITED (LISTED CO.)
- 5. 15 MONTHS WITH RELIANCE PETROCHEMICALS LIMITED (LISTED CO.)
- 6. 15 MONTHS WITH LAN ESEDA GROUP OF COMPANIES (LISTED)
- 7. 12MONTHS WITH POOJA CAPITAL FINANCE LIMITED (UNLISTED)

#### EXPERIENCE AS FULL TIME PRACTICING COMPANY SECRETARY: -

SINCE 1995 I HAVE MY INDEPENDENT PRACTICE AND HOLDING CERTIFICATE OF PRACTICE FROM MORE THAN 15 YEARS.

HAVE PRACTICAL EXPERIENCE OF 35 YEARS IN ADMISTRATION OF THE PROVISIONS OF THE COMPANIES ACT, 1956/2013, SEBI GUIDELINES, STOCK EXCHANGE FORMALITIES, AND COMPANY LAW BOARD MATTERS.

## PERSONAL DETAILS:

DATE OF BIRTH: - 16TH APRIL1956.

ADDRESS: - OM SRI CHS LTD., A WING, FIRST FLOOR, FLAT NO 7. NEAR SHANTI ASHRAM, OFF LINK ROAD, BORIVALI (WEST), MUMBAI 400103.

MEMBERSHIP NO.: - FCS 1391

COP NO.: - 3888

LANGUAGES KNOWN: - ENGLISH, HINDI, MARATHI, GUJRATHI AND MARWARI